References
- Berger EA . Finding fusin/CXCR4, the first '2nd receptor' for HIV entry. Front. Immunol.6, 283 (2015).
- De Clercq E . The bicyclam AMD3100 story. Nat. Rev. Drug Discov.2 (7), 581–587 (2003).
- Wilkin TJ , GulickRM. CCR5 antagonism in HIV infection: current concepts and future opportunities. Annu. Rev. Med.63, 81–93 (2012).
- Didigu CA , DomsRW. Novel approaches to inhibit HIV entry. Viruses4 (2), 309–324 (2012).
- Fricker SP , MetzM. Chemokine receptor modeling: an interdisciplinary approach to drug design. Future Med. Chem.6 (1), 91–114 (2014).
- Van Der Ryst E . Maraviroc – A CCR5 antagonist for the treatment of HIV-1 infection. Front. Immunol.6, 277 (2015).
- Parra J , PortillaJ, PulidoFet al. Clinical utility of maraviroc. Clin. Drug Investig.31 (8), 527–542 (2011).
- Llibre JM , RiveroA, RojasJFet al. Safety, efficacy and indications of prescription of maraviroc in clinical practice: factors associated with clinical outcomes. Antiviral Res.120, 79–84 (2015).
- Gerlach LO , SkerljRT, BridgerGJ, SchwartzTW. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J. Biol. Chem.276 (17), 14153–14160 (2001).
- Skerlj RT , BridgerGJ, KallerAet al. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J. Med. Chem.53 (8), 3376–3388 (2010).
- Moyle G , DejesusE, BoffitoMet al. Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1. Clin. Infect. Dis.48 (6), 798–805 (2009).
- Pusic I , DipersioJF. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Curr. Opin. Hematol.17 (4), 319–326 (2010).
- Vicenzi E , LiòP, PoliG. The puzzling role of CXCR4 in human immunodeficiency virus infection. Theranostics3 (1), 18–25 (2013).
- Wilen CB , TiltonJC, DomsRW. HIV: cell binding and entry. Cold Spring Harb. Perspect. Med.2 (8), pii: a006866 (2012).
- Passaes CP , Sáez-CiriónA. HIV cure research: advances and prospects. Virology454–455, 340–352 (2014).
- Sierra-Enguita R , RodriguezC, AguileraAet al. X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain. AIDS28 (11), 1603–1609 (2014).
- Teicher BA , FrickerSP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin. Cancer. Res.16 (11), 2927–2931 (2010).
- Zhao H , ProsserAR, LiottaDC, WilsonLJ. Discovery of novel N-aryl piperazine CXCR4 antagonists. Bioorg. Med. Chem. Lett. doi:10.1016/j.bmcl.2015.04.036 (2015) ( Epub ahead of print).
- Allers K , SchneiderT. CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy. Curr. Opin. Virol.14, 24–29 (2015).